1st-line treatment of postmenopausal women w/ hormone receptor +ve or hormone receptor unknown locally advanced or metastatic breast cancer. Advanced breast cancer in postmenopausal women w/ disease progression after tamoxifen therapy. Adjuvant treatment of postmenopausal women w/ hormone receptor +ve early breast cancer.
Hypersensitivity. Premenopausal women. Severe renal failure; moderate or severe hepatic failure. Concomitant use of selective estrogen receptor modulators & other aromatase inhibitors. Pregnancy & lactation. Childn.
Postmenopausal women at high risk for osteoporosis. Monitor serum lipoprotein conc for long-term therapy. Patients w/ osteoporosis or osteopenia. May impair ability to drive or operate machinery. Childn <18 yr.
Selective estrogen receptor modulators (eg, tamoxifen, raloxifene) & aromatase inhibitors (eg, exemestane, formestane, letrozole). Action may be diminished by estrogens. May inhibit in vitro metabolic reactions catalyzed by cytochrome P-450 isoenzymes 1A2, 2C8/9 & 3A4 (but only at high conc).